Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aligos Therapeutics, Inc. (ALGS : NSDQ)

• Company Description    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif. Number of Employees: 82

• Price / Volume Information    Yesterday's Closing Price: $6.66 Daily Weekly Monthly 20 Day Moving Average: 43,465 shares Shares Outstanding: 6.19 (millions) Market Capitalization: $41.21 (millions) Beta: 2.67 52 Week High: $13.69 52 Week Low: $3.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.26% 2.32% 12 Week -27.05% -21.45% Year To Date -28.54% -23.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE CORPORATE DR. 2ND FLOOR - SOUTH SAN FRANCISCO,CA 94080 USA ph: 800-466-6059 fax: - jtarazi@aligos.com http://www.aligos.com

• General Corporate Information    Officers Lawrence M. Blatt - Chairman; President; and Chief Executive Officer Lesley Ann Calhoun - Executive VP; Chief Operating Officer & C.F.O Nikhil Aneja - VP Finance James Scopa - Director Bridget Martell - Director Peer Information Aligos Therapeutics, Inc. (CORR.) Aligos Therapeutics, Inc. (RSPI) Aligos Therapeutics, Inc. (CGXP) Aligos Therapeutics, Inc. (BGEN) Aligos Therapeutics, Inc. (GTBP) Aligos Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 01626L204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 6.19 Most Recent Split Date: 8.00 (0.04:1) Beta: 2.67 Market Capitalization: $41.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: - Price / Sales: 18.85 EPS Growth vs. Year Ago Period: 43.99% vs. Previous Quarter: 37.17% Sales Growth vs. Year Ago Period: -73.13% vs. Previous Quarter: -77.19% ROE 12/31/25 - -28.16 09/30/25 - -39.35 06/30/25 - -22.41 ROA 12/31/25 - -20.01 09/30/25 - -22.09 06/30/25 - -12.09 Current Ratio 12/31/25 - 3.90 09/30/25 - 4.70 06/30/25 - 6.31 Quick Ratio 12/31/25 - 3.90 09/30/25 - 4.70 06/30/25 - 6.31 Operating Margin 12/31/25 - -1,106.72 09/30/25 - -970.90 06/30/25 - -422.56 Net Margin 12/31/25 - -1,106.72 09/30/25 - -3,267.65 06/30/25 - -2,337.24 Pre-Tax Margin 12/31/25 - -1,092.36 09/30/25 - -3,255.90 06/30/25 - -2,326.34 Book Value 12/31/25 - 8.67 09/30/25 - 11.67 06/30/25 - 16.56 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.17 06/30/25 - 0.12

Powered by Zacks Investment Research ©